Reviews/ACE Inhibitors and Angiotensin Receptor Blockers/Hyperkalemia limits ACE inhibitor and ARB use in chronic kidney disease
Renal · ACEARB-RENAL-04 · v2
Across several different health systems, when CKD patients on ACE inhibitors or ARBs develop high blood potassium, doctors frequently cut the dose or stop the drug entirely [7][24][16]. Stopping these drugs is linked to worse heart and kidney outcomes [6][18], yet the drugs themselves protect the kidneys [1][2] and high potassium can often be controlled with a potassium binder rather than by stopping the drug [3]. That combination is why the panel saw much of this stopping as avoidable. The word 'inappropriate', however, is a judgment the studies never actually measured, and in some cases stopping is the correct, even life-saving, decision [15]. The harm evidence also comes from observational cohorts, where sicker patients may both stop the drug and fare worse for other reasons.
Independent cohorts converge on the first part of the claim: hyperkalemia commonly triggers RAASi discontinuation or down-titration in CKD, with 46.6% of patients having a regimen change after an episode in one Australian cohort [7] and 48% having their ACE-I/ARB reduced or discontinued in a VA review [24]. Discontinuation is associated with higher risk of MACE (HR 1.27), heart failure (HR 1.85) and ESKD (HR 1.30) [6], and accelerated eGFR decline [18]. The drugs are renoprotective, with losartan reducing ESRD risk by 28% [1], while patiromer lowers potassium and prevents recurrent hyperkalemia (recurrence 60% on placebo vs 15% on patiromer) [3], establishing that much discontinuation is avoidable. Second-generation potassium binders were associated with higher RAASi persistence (76.9% vs 66.4%) and lower observed mortality [16]. The contested point: The division is over the second limb, 'inappropriate': the corpus never operationalises or measures appropriateness, and [15] documents 25 cases of life-threatening hyperkalemia where stopping is medically correct. The harm limb rests on observational cohorts open to confounding by indication, and in [6] discontinued users had neutral hyperkalemia risk (HR 0.95, 95% CI 0.84-1.08), complicating the premise that hyperkalemia is the dominant driver.
All 25 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from ACE Inhibitors and Angiotensin Receptor Blockers, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
'Inappropriate' is a clinical value judgment the corpus never operationalises or measures; [15] documents 25 cases of life-threatening hyperkalemia with ACEi plus spironolactone where discontinuation is medically correct, so the blanket characterisation overreaches the claim's exact wording.
The harm limb rests on observational cohorts ([6], [24], [18]) vulnerable to confounding by indication: patients whose RAASi is discontinued are sicker and have worse prognoses, so association with MACE, HF and ESKD cannot establish that discontinuation itself is causally harmful.
Where it remains uncertain. The harm evidence is observational and confounded by indication, and severe hyperkalemia sometimes makes discontinuation correct [15], so the blanket label 'inappropriate' is not established by direct measurement.
Aleatory
Whether a given episode is mild and manageable or life-threatening differs patient to patient [15][24], so the same claim covers cases where discontinuation is avoidable and cases where it is correct.
Epistemic
No corpus study operationalises or records whether a discontinuation was clinically justified; the 'inappropriate' limb is inferred from benefit and manageability, not observed.
Inferential
Patients whose RAASi is discontinued may be sicker at baseline, so the MACE, HF and ESKD associations in [6][24] may reflect prognosis rather than the act of stopping.
The load-bearing papers from a corpus of 25, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Anchors the renoprotective benefit that discontinuation forgoes.
“Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated.”
Panel auditInternal validity: high · scope of inference: Efficacy of losartan on renal/cardiovascular outcomes in type 2 diabetes with established nephropathy.Key limitations: no discontinuation outcome · not about hyperkalemia management · diabetic nephropathy only
Establishes hyperkalemia as a constraint on RAASi use that pharmacologic management can relieve (avoidable discontinuation).
“Hyperkalemia increases the risk of death and limits the use of inhibitors of the renin-angiotensin-aldosterone system (RAAS) in high-risk patients.”
Panel auditInternal validity: high · scope of inference: Efficacy of patiromer in lowering potassium in CKD patients on RAASi with hyperkalemia.Key limitations: discontinuation not an endpoint · appropriateness not assessed · surrogate potassium endpoint
RCT evidence that stopping RAS inhibitors confers no eGFR benefit, consistent with discontinuation being unwarranted.
“Among patients with advanced and progressive chronic kidney disease, the discontinuation of RAS inhibitors was not associated with a significant between-group difference in the long-term rate of decrease in the eGFR.”
Panel auditInternal validity: high · scope of inference: Effect of planned RAS-inhibitor discontinuation on eGFR in advanced, progressive CKD.Key limitations: discontinuation not hyperkalemia-triggered · open-label · ESKD HR trend not significant
It describes severe hyperkalemia cases, not the frequency or appropriateness of ACEi/ARB discontinuation.
Panel auditInternal validity: low · scope of inference: Severe hyperkalemia risk with combined ACE inhibitor and spironolactone in renal insufficiency.Key limitations: case series, no comparator · spironolactone combination · selected severe cases
4 of 25 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The occurrence of hyperkalemia-driven discontinuation is robustly evidenced and its inappropriateness is well-supported by benefit, manageability and harm data, but reliance on observational studies and the value-laden wording cap confidence below Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No trial of binder-enabled continuation versus discontinuation. The claim's inappropriateness hinges on continuation being both feasible and beneficial; the corpus shows binders lower potassium [3] and associate with persistence [16] but no trial links that to cardiorenal outcomes. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: RCT randomising CKD patients with RAASi-associated hyperkalemia to potassium-binder-enabled RAASi continuation versus discontinuation, with MACE, HF and ESKD endpoints.
Open question: Does maintaining ACEi/ARB therapy with a potassium binder after hyperkalemia improve cardiorenal outcomes compared with discontinuation? Why it is still open: Binders lower potassium [3] and associate with higher RAASi persistence and lower observed mortality [16], but no corpus trial tests outcomes of the continuation-versus-discontinuation decision itself.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19